About Align Technology, Inc. - Common Stock (ALGN)
Align Technology is a medical device company known primarily for its innovative dental products, including the Invisalign system, which offers a clear alternative to traditional metal braces for orthodontic treatment. The company focuses on transforming patients' smiles through advanced 3D computer modeling and digital scanning technologies, enabling customized treatment plans. In addition to its flagship product, Align Technology also produces a range of other tools and software that enhance dental practice efficiency and patient care, serving both orthodontists and general dentists. By combining cutting-edge technology with a commitment to improving oral health, Align Technology aims to empower patients and revolutionize the field of orthodontics. Read More
Shares of dental technology company Align Technology (NASDAQ:ALGN)
jumped 6.1% in the morning session after the company reported strong third-quarter results that beat revenue and earnings forecasts, driven by higher demand for its Invisalign clear aligners. Revenue for the quarter reached $995.7 million, up 1.8% from the previous year, while adjusted earnings came in at $2.61 per share, both surpassing Wall Street's expectations. The positive results were supported by a 4.9% year-on-year increase in clear aligner sales volumes. Looking ahead, Align Technology provided a forecast for the fourth quarter, expecting revenue to be around $1.04 billion, which was roughly in line with analysts' projections.
Stay updated with the movements of the S&P500 index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session.
Dental technology company Align Technology (NASDAQ:ALGN) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 1.8% year on year to $995.7 million. The company expects next quarter’s revenue to be around $1.04 billion, close to analysts’ estimates. Its non-GAAP profit of $2.61 per share was 8.4% above analysts’ consensus estimates.
Dental technology company Align Technology (NASDAQ:ALGN) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 1.8% year on year to $995.7 million. The company expects next quarter’s revenue to be around $1.04 billion, close to analysts’ estimates. Its non-GAAP profit of $2.61 per share was 8.4% above analysts’ consensus estimates.
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top S&P500 gainers and losers shaping the post-market sentiment.
Align Technology's Q3 earnings show a mixed picture, beating EPS estimates with $2.61 while revenue was in-line. Clear aligner volume grew 4.9% year-over-year.
Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today reported financial results for the third quarter ("Q3'25"). Q3'25 total revenues were $995.7 million, down 1.7% sequentially and up 1.8% year-over-year. Q3'25 total revenues were favorably impacted by foreign exchange of approximately $11.7 million, or 1.2% sequentially, and favorably impacted by approximately $15.6 million, or 1.6% year-over-year.(1) Q3'25 Clear Aligner revenues were $805.8 million, up 0.1% sequentially and up 2.4% year-over-year. Q3'25 Clear Aligner revenues were favorably impacted by foreign exchange of approximately $9.8 million, or 1.2% sequentially, and favorably impacted by approximately $13.0 million, or 1.6% year-over-year.(1) Q3'25 Clear Aligner volume was up 0.5% sequentially and up 4.9% year-over-year. Q3'25 Imaging Systems and CAD/CAM Services revenues were $189.9 million, down 8.6% sequentially, and down 0.6% year-over-year. Q3'25 Imaging Systems and CAD/CAM Services revenues were favorably impacted by foreign exchange of approximately $1.8 million, or 1.0% sequentially and favorably impacted by approximately $2.6 million, or 1.4% year-over-year.(1)
Align Technology, Inc. (NASDAQ: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software, today announced ClinCheck® Live Plan, a new feature in its Invisalign® digital treatment planning that automates the generation of initial doctor-ready treatment plans within 15 minutes. This advancement represents a major technological milestone in the Align™ Digital Platform, that can reduce the Invisalign treatment planning cycle from days to minutes.
Align Technology, Inc. (NASDAQ: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software, today announced a series of new product innovations for iTero™ Digital Solutions, a comprehensive ecosystem that includes intraoral scanners and integrated software tools that are designed to transform dental consultations into a modern, multi-modal oral health assessment that helps doctors and their teams deliver exceptional chairside experiences in support of Invisalign treatment conversion1. These new capabilities span across key practice workflows that underline the Align™ Digital Workflow including Diagnose, Plan, Treat, and Monitor steps. From dynamic and personalized visualization and patient engagement tools at chairside, to expanded compatibility with 3D printers and milling machines, these new innovations simplify workflows, increase patient acceptance1, and drive practice growth.2
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently -
over the past six months, the collective 13.6% gain for healthcare stocks has fallen short of the S&P 500’s 25.5% rise.
Align Technology’s stock price has taken a beating over the past six months, shedding 23% of its value and falling to $128.81 per share. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.
As the Q3 2025 earnings season unfolds, corporate America is delivering a powerful narrative of resilience and growth, significantly influencing overall stock market movements. Despite a complex backdrop of economic uncertainties and geopolitical tensions, stronger-than-expected corporate performances are largely driving a prevailing sense of optimism among investors. This robust earnings
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices.
But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.
